Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InspireMD (NSPR) Current Deferred Revenue (2016 - 2020)

Historic Current Deferred Revenue for InspireMD (NSPR) over the last 11 years, with Q3 2020 value amounting to $19000.0.

  • InspireMD's Current Deferred Revenue changed 0.0% to $19000.0 in Q3 2020 from the same period last year, while for Sep 2020 it was $19000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $20000.0 for FY2019, which is 2000.0% down from last year.
  • Latest data reveals that InspireMD reported Current Deferred Revenue of $19000.0 as of Q3 2020, which was down 0.0% from $17000.0 recorded in Q2 2020.
  • In the past 5 years, InspireMD's Current Deferred Revenue registered a high of $111000.0 during Q2 2016, and its lowest value of $17000.0 during Q1 2020.
  • Over the past 5 years, InspireMD's median Current Deferred Revenue value was $25000.0 (recorded in 2018), while the average stood at $30222.2.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first plummeted by 8023.95% in 2016, then skyrocketed by 2500.0% in 2018.
  • Over the past 5 years, InspireMD's Current Deferred Revenue (Quarter) stood at $33000.0 in 2016, then plummeted by 39.39% to $20000.0 in 2017, then increased by 25.0% to $25000.0 in 2018, then dropped by 20.0% to $20000.0 in 2019, then fell by 5.0% to $19000.0 in 2020.
  • Its Current Deferred Revenue stands at $19000.0 for Q3 2020, versus $17000.0 for Q2 2020 and $17000.0 for Q1 2020.